Status:
TERMINATED
Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer
Lead Sponsor:
Matthew Neal MD
Conditions:
Pancreatic Neoplasms
Rectal Neoplasms
Eligibility:
All Genders
19-80 years
Phase:
NA
Brief Summary
This study will evaluate light therapy used in combination with standard therapies for pancreatic and rectal cancer. Participants will receive chemotherapy, radiation, and surgical treatments identica...
Detailed Description
The investigators incorporate appropriate control participants, which include participants who are matched for stage and age and who undergo neoadjuvant chemoradiation and/or surgery but who are not e...
Eligibility Criteria
Inclusion
- greater than 18 and less than 80 years of age
- adenocarcinoma of the pancreas (unresectable) or adenocarcinoma of the rectum (stage II or III).
Exclusion
- Prior chemotherapy (inability to determine the integrity of the immune response)
- Autoimmune disorder, immunosuppression therapy, or immunocompromised state (inability to determine the integrity of the immune response)
- Blindness or other significant vision disorder or prior traumatic brain injury (the inability to determine the integrity of functional optic and suprachiasmatic pathways)
- Hematological disease - e.g., myelodysplastic syndrome, leukemia (inability to determine the integrity of the immune response)
- Bipolar disorder or schizophrenia (potential heightened symptoms)
- Refusal/ineligible to undergo neoadjuvant chemotherapy and/or radiation
Key Trial Info
Start Date :
August 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 29 2023
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT06164691
Start Date
August 14 2022
End Date
April 29 2023
Last Update
May 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213